Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.

Jiri BronskyIvana CopovaDenis KazekaTereza LerchovaKatarina MitrovaKristyna PospisilovaMiroslava SulovcovaKristyna ZarubovaOndrej Hradsky

Published in: Clinical and translational gastroenterology (2022)

Propensity score matching did not reveal substantial differences in efficacy or safety between ADA and IFX. The anti-S. cerevisiae antibody negativity and antineutrophil cytoplasmic antibody positivity combination is a strong predictor of treatment escalation.

Keyphrases

rheumatoid arthritis
open label
ulcerative colitis
replacement therapy
dna methylation
juvenile idiopathic arthritis
data analysis
disease activity